|
|
|
| Analysis of the relationship between carcinoembryonic antigen level and radiotherapy effect in patients with locally advanced non-small cell lung cancer |
| ZONG Chunmei ZHAO Lin SUN Wei▲ |
Ward Three, Department of Oncology, Huaibei People’s Hospital, Anhui Province, Huaibei 235000, China
|
|
|
|
Abstract Objective To study the relationship between the carcinoembryonic antigen (CEA) level and radiotherapy effect in patients with locally advanced non-small cell lung cancer (NSCLC). Methods A total of 89 patients with locally advanced NSCLC received radiotherapy in the Department of Oncology, Huaibei People’s Hospital, Anhui Province from January 2019 to December 2021 were selected and evaluated according to response evaluation criteria in solid tumor 1.1 one month after the end of radiotherapy. Patients with complete response and partial response were included in the radiotherapy sensitive group (41 cases). The rest were included in the radiotherapy resistance group (48 cases). The differences of serum CEA level before radiotherapy, and other clinical data between the two groups were analyzed. Logistic regression analysis and receiver operating characteristic (ROC) curve were used to evaluate the relationship between serum CEA level before radiotherapy and radiotherapy effect. Results The radiotherapy resistance rate of 89 patients was 53.93%. The age of diagnosis, the proportion of the maximum diameter of primary tumor ≥5.0 cm, the proportion of low differentiation, and the serum CEA level before radiotherapy in the radiotherapy resistance group were higher than those in the radiotherapy sensitive group, the differences were statistically significant (P＜0.05). Multivariate analysis showed that age of diagnosis, the proportion of low differentiation, and serum CEA level before radiotherapy were all factors influencing radiotherapy resistance in NSCLC patients (P＜0.05). ROC curve analysis showed that the area under the curve of serum CEA before radiotherapy in predicting radiotherapy resistance of NSCLC patients was 0.887 (P＜0.05). Conclusion Serum CEA level before radiotherapy is a influencing factor for radiotherapy resistance in patients with locally advanced NSCLC, and has a certain value in predicting radiotherapy effect.
|
|
|
|
|
|
[1] 袁蕙芸，蒋宇飞，谭玉婷，等.全球癌症发病与死亡流行现状和变化趋势[J].肿瘤防治研究，2021，48（6）：642-646.
[2] Pilleron S，Soto-Perez-de-Celis E，Vignat J，et al. Estimated global cancer incidence in the oldest adults in 2018 and projections to 2050 [J]. Int J Cancer，2021，148（3）：601- 608.
[3] 陈猛，陆晓蕾，朱琼啸，等.基于多属性效用理论评估晚期非小细胞肺腺癌常用化疗方案[J].中国药物应用与监测，2021，18（1）：1-4.
[4] 罗青竹，丁广成，时昌立，等.立体定向放疗联合唑来膦酸治疗非小细胞肺癌脊柱转移疗效分析[J].中国医药科学，2021，11（22）：173-176.
[5] Mehta A，Parkash A，Bhatia M. Cross-sectional study to establish the utility of serum tumor markers in the diagnosis of lung cancer [J]. Asian Pac J Cancer Prev，2021，22（8）：2569- 2576.
[6] 武颖，龚正，刘航，等.多种血清肿瘤标志物联合检测对原发性肝癌的诊断价值[J].中国医药科学，2022，12（5）：142-146.
[7] Wang J，Chu Y，Li J，et al. Development of a prediction model with serum tumor markers to assess tumor metastasis in lung cancer [J]. Cancer Med，2020，9（15）：5436-5445.
[8] Khushk M，Khan A，Rehman A，et al. The role of tumor markers：Carcinoembryonic antigen and cancer antigen 15-3 in patients with breast cancer [J]. Cureus，2021，13（7）：e16298.
[9] 中华医学会，中华医学会肿瘤学分会，中华医学会杂志社.中华医学会肺癌临床诊疗指南（2018版）[J].肿瘤研究与临床，2018，30（12）：793-824.
[10] 陈炎，陈亚蓓，陶荣芳.《CSCO原发性肺癌诊疗指南2016》非小细胞肺癌治疗内容介绍[J].中国实用内科杂志，2017， 57（1）：35-37.
[11] 刘阳阳.CyCAR标准与RECIST标准在一线应用贝伐珠单抗治疗晚期非鳞非小细胞肺癌疗效评价中的比较[J].山西医药杂志，2021，50（20）：2870-2873.
[12] 胡翔，陈猛，吴承骏，等.Cofilin1及其Ser3位点磷酸化与老年非小细胞肺癌患者放疗敏感性的相关性研究[J].肿瘤药学，2022，12（2）：221-227.
[13] 许广辉，丁成智，王国磊，等.EGFR突变检测对非小细胞肺癌患者术后复发转移部位的预测价值[J].现代肿瘤医学，2020，28（13）：2238-2241.
[14] 高金龙.晚期胆道恶性肿瘤患者放化疗联合靶向治疗的疗效探讨[J].中国药物与临床，2020，20（21）：3629-3631.
[15] 周珊，温莹浩，朱泽文，等.三维适形放疗与静态调强放疗治疗局部晚期非小细胞肺癌的临床疗效和剂量学参数及对免疫功能的影响[J].癌症进展，2020，18（23）：2421- 2423.
[16] Tu Y，Wu Y，Lu Y，et al. Development of risk prediction models for lung cancer based on tumor markers and radio- logical signs [J]. J Clin Lab Anal，2021，35（3）：e23682.
[17] 王宁，付立业，隋承光，等.胃癌患者血清中IGF-1与CEA、CA125、CA199、CA724水平的相关性分析及在胃癌诊断中的意义[J].中国实验诊断学，2021，25（2）：194- 197.
[18] 潘春燕，李凤菊，陶亚飞，等.磁共振扩散加权成像联合血清AFP、CA125、CEA、CA199检测在早期原发性肝癌中的诊断价值研究[J].现代生物医学进展，2021，21（23）：4527-4530.
[19] Furuta T，Oda T，Kiyoi K，et al. Carcinoembryonic antigen as a specific glycoprotein ligand of rBC2LCN lectin on pancreatic ductal adenocarcinoma cells [J]. Cancer Sci，2021，112（9）：3722-3731.
[20] Lakemeyer L，Sander S，Wittau M，et al. Diagnostic and prognostic value of CEA and CA19-9 in colorectal cancer [J]. Diseases，2021，9（1）：21.
[21] 林荣军，陈振奋，杨丽萍，等.血清胃蛋白酶原联合肿瘤标志物CEA、CA199、CA125在胃癌诊断中的价值研究[J].中国当代医药，2021，28（35）：184-186.
[22] 张侠，李鹏，尚红妍.血清TK1 CEA CA72-4和CA242联合检测对胃癌的诊断价值[J].河北医学，2021，27（3）：494-499.
[23] 彭振宇，雷小林，杨蕾，等.自拟解毒利咽汤联合调强适形放射治疗晚期鼻咽癌的效果及对血清CEA、SCCAg的影响[J].疑难病杂志，2022，21（9）：944-948.
[24] 刘曦，王海东，吴蔚，等.血清肿瘤坏死因子受体相关蛋白1水平及癌组织癌胚抗原表达与中晚期食管鳞癌化疗效果的相关性[J].中华实用诊断与治疗杂志，2021， 35（9）：872-875.
[25] 熊咏，沈容荣，刘东洋.血清中白细胞介素-6及癌胚抗原对结直肠癌术后复发的预测作用[J].中国当代医药，2022，29（2）：11-14.
[26] 王敏，张梦馨，黄辉，等.培元抗癌汤联合放化疗对非小细胞肺癌患者临床缓解率及血清鳞状上皮细胞癌抗原和癌胚抗原水平的影响[J].中国医药，2022，17（12）：1791- 1794.
[27] 朱艳，王瑞凯，李阿敏，等.培美曲塞联合顺铂治疗晚期非小细胞肺癌患者对CEA等标志物表达的影响[J].疑难病杂志，2021，20（10）：982-986.
[28] Li J，Chen Y，Wang X，et al. The value of combined detection of CEA，CYFRA21-1，SCC-Ag，and pro-GRP in the differential diagnosis of lung cancer [J]. Transl Cancer Res，2021，10（4）：1900-1906.
[29] Sun J，Chen X，Wang Y. Comparison of the diagnostic value of CEA combined with OPN or DKK1 in non-small cell lung cancer [J]. Oncol Lett，2020，20（3）：3046-3052.
[30] Kuo YS，Zheng MY，Huang MF，et al. Association of diver- gent carcinoembryonic antigen patterns and lung cancer progression [J]. Sci Rep，2020，10（1）：2066.
[31] 马丽娟，王蕴，李殿明.血清CEA、D-D、ALB、NLR与非小细胞肺癌的相关性及联合诊断价值分析[J].标记免疫分析与临床，2021，28（9）：1537-1541.
[32] 薛文姬，毕楠，杨琳，等.PD-L1在同步放化疗非EGFR突变局部晚期非小细胞肺癌中的表达及其与患者预后的关系[J].中华医学杂志，2022，102（6）：406-411. |
|
|
|
